INC Featured Speakers

INC Featured Speakers
Sunday 28 June, 2020

Michael P. Collins, MD, Medical College of Wisconsin, Milwaukee, WI, USA 
Title: 
Vasculitic neuropathies: Updates in classification, pathology, and treatment

 

Coming Soon

 


Charlotte Teunissen, PhD  Neurochemistry Lab, Amsterdam University Medical Centers, Amsterdam, Netherlands

Title: Novel Opportunities for Body Fluid Biomarker Development for Neurological Diseases

   

There is a strong potential in the use of body fluid biomarkers for different clinical purposes in neurological diseases. Such biomarkers can aid in diagnosis, prognosis, patient stratification and treatment effect monitoring. This value of biomarkers is exemplified by current use in diagnosis and follow-up of patients. This does for example include the analysis of cerebrospinal fluid (CSF) in Alzheimer´s disease for tau protein and abeta-peptides, the search for aquaporin autoantibodies in neuromyelitis optica. Rapid technological developments offer opportunities to develop novel and specific body fluid biomarkers, even in blood. This is shown by the use of blood neurofilament light chain in a variety of neurological diseases.


Stephen W. Reddel, PhD University of Sydney, Sydney, Australia  
Title: 
Beyond Immunoglobulin and Steroids in CIDP: What can we learn from other diseases?

   

The established treatment options for CIDP are quite limited, to short term suppressive Ig based therapies (IVIG, SCIG, PLEX) and corticosteroids with their problematic long term side effects. The reasons behind this include disease rarity, heterogeneity, and that it is rarely life-threatening, all of which have contributed to the lack of an evidence base for other longer term and potentially more effective immunotherapies. Nonetheless other treatments often have to be tried in individual CIDP patients, without the trial evidence base. A knowledge base exists in other neurological diseases, including MG, MS and the MOG antibody and NMO variants. This gives some insights into which treatments should be considered and for which subgroups of CIDP, for how long an N=1 treatment trial should continue, and the comparative risks arising.

 

INC Featured Speakers
Monday 29 June, 2020

Luis Querol, MD, PhD, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain  
Title:
Antibodies in Inflammatory Neruopathies: What to test, how to test, why to test

            Autoantibodies play an important role in the pathogenesis of inflammatory neuropathies. These antibodies are very diverse in their nature, target antigens, testing procedures and clinical implications. Inconsistent results and poor testing standards may then lead to inappropriate conclusions and poor therapeutic choices. The talk will review the different autoantibodies described in the literature focusing in their clinical utility and test caveats and will provide a diagnostic workflow in the detection of autoantibodies in inflammatory neuropathies.


Kazim Sheikh, MD, Department of Neurology - McGovern Medical School, Houston, TX, USA
Title: The Role of Fc Receptors in Inflammatory Neuropathy: Emerging Targets for Novel Therapies

   

 

 

 

Thank you to our 2019 PNS Sponsors!